比较钆贝葡胺与钆塞酸二钠增强MRI对肝细胞癌高危患者LI-RADS 2014版主要征象的显示率
回顾性匹配队列研究比较钆贝葡胺与钆塞酸二钠增强肝脏MRI对LI-RADS 2014版主要征象的显示率,钆贝葡胺组63例130个结节、钆塞酸二钠组64例117个结节,动脉期高强化显示率相似,而动态期廓清和包膜征象在钆贝葡胺组更常见。
要点
- 动脉期高强化显示率两种对比剂相似(钆贝葡胺91.5% vs 钆塞酸二钠88.0%,p=0.173)。
- 动态期廓清钆贝葡胺组60.2%高于钆塞酸二钠组45.3%(p=0.006)。
- 包膜征象钆贝葡胺组50.2%高于钆塞酸二钠组33.3%(p<0.001)。
核心结论
- 两种对比剂动脉期高强化显示率相似,但动态期廓清和包膜征象在钆贝葡胺增强MRI上更常被显示。
研究设计与样本
- 回顾性研究,采用年龄、性别、基础肝病和肝硬化进行匹配,钆贝葡胺组63例130个结节(中位大小1.9 cm),钆塞酸二钠组64例117个结节(中位大小2.0 cm),由3名放射科医师独立评估LI-RADS主要征象。
诊断标准与关键数值
- 动脉期高强化显示率:钆贝葡胺组平均91.5%(119/130)vs 钆塞酸二钠组平均88.0%(103/117),p=0.173。
- 动态期廓清显示率:钆贝葡胺组平均60.2%(78.3/130)vs 钆塞酸二钠组平均45.3%(53/117),p=0.006。
- 包膜征象显示率:钆贝葡胺组平均50.2%(65.3/130)vs 钆塞酸二钠组平均33.3%(39/117),p<0.001。
- 动脉期强化和动态期廓清的读者间一致性在两种对比剂均几乎完美(κ>0.83)。
- 包膜征象读者间一致性:钆贝葡胺组中等(κ=0.52),钆塞酸二钠组显著(κ=0.67)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The purpose of this study is to compare visualization rates of the major features covered by Liver Imaging Reporting and Data System (LI-RADS) version 2014 in patients at risk for hepatocellular carcinoma using either gadobenate dimeglumine or gadoxetate disodium IV contrast agent.
MATERIALS AND METHODS: This retrospective study included liver MRI examinations performed with either gadobenate dimeglumine or gadoxetate disodium contrast enhancement. Using age, sex, underlying liver disease, and presence of cirrhosis, patients were placed into matched cohorts. All hepatic nodules 1 cm or larger (up to five per subject) were included, resulting in 63 subjects with 130 nodules (median nodule size, 1.9 cm) imaged with gadobenate and 64 subjects with 117 nodules (median nodule size, 2.0 cm) imaged with gadoxetate. Three radiologists reviewed the studies for LI-RADS major features independently. Bootstrap resampling with 10,000 repetitions was used to compare feature detection rates.
RESULTS: Arterial phase hyperenhancement was seen in a similar number of nodules with gadobenate dimeglumine (mean, 91.5% [119/130]) and gadoxetate disodium (mean, 88.0% [103/117]) (p = 0.173). Dynamic phase washout was more commonly seen with gadobenate dimeglumine (mean, 60.2% [78.3/130]) than with gadoxetate disodium (mean, 45.3% [53/117]) (p = 0.006). The capsule feature was more often visualized with gadobenate dimeglumine (mean, 50.2% [65.3/130]) than with gadoxetate disodium (mean, 33.3% [39/117]) (p < 0.001). Interreader agreement for arterial phase enhancement and dynamic phase washout was almost perfect for both contrast agents (κ > 0.83). Agreement for the capsule feature was moderate for gadobenate dimeglumine (κ = 0.52) and substantial for gadoxetate disodium (κ = 0.67).
CONCLUSION: The rates of visualization of arterial phase hyperenhancement are similar in studies performed with gadobenate dimeglumine and gadoxetate disodium, but dynamic phase washout and capsule appearance are more commonly visualized with gadobenate dimeglumine.
引用
- Allen BC, Ho LM, Jaffe TA, et al. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma. AJR Am J Roentgenol. 2018. PMID: 29629800. doi:10.2214/AJR.17.18981
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。